We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Bio-Techne Corporation is a global life sciences company. It develops, manufactures, and sells biotechnology products and clinical diagnostic controls. It provides proteins, such as cytokines, growth factors, and enzymes; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits; and clinical diagnostic immunoassay kits. The Company also offers flow cytometry products; natural and synthetic chemical compounds; hematology controls and calibrators; and hematology control products. Bio-Techne Corporation, formerly known as Techne Corporation, is headquartered in Minneapolis, Minnesota.
- Recent TECH Stock Price: $374.43
- Yearly Gain for TECH stock: -17.67%
- Market Cap for TECH stock: $14.91B
- P/E Ratio for TECH stock: 57.331
Will TECH's stock price go up? Is there an accurate TECH stock forecast available?
TipRanks.com reports that Bio-Techne currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $494.43. The target pricing ranges from a high TECH forecast of $580.00 down to a low forecast of $390.00. Bio-Techne (TECH)’s last closing stock price was $374.43 which would put the average price target at 32.05% upside.
In addition, TradingView issued a Neutral rating for TECH stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on TECH stock.
Other analysts covering TECH include:
- Alexander Nowak of Craig-Hallum issued a Buy rating with the price target of $ 501 on 6 days ago
- Catherine Ramsey Schulte of Robert W. Baird issued a Buy rating with the price target of $ 470 on 1 week ago
- Daniel Arias of Stifel Nicolaus issued a Buy rating with the price target of $ 500 on 1 week ago
- Puneet Souda of SVB Securities issued a Buy rating with the price target of $ 580 on 1 week ago
If you are wondering if TECH is a good stock to buy, here are 3rd party ratings for TECH stock:
- TipRanks.com: Strong Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Buy, Top 33% (82 out of 252)
What is the sentiment on the street regarding Bio-Techne? (Current ratings compiled by TipRanks.com)
- News Sentiment for TECH stock: Very Bullish
- Blogger Consensus for TECH stock: Bullish
- Media Buzz for TECH stock: Medium
- Insider Signal for TECH stock: Neutral
- Investor Sentiment for TECH stock: Very Positive
- Hedge Fund signal for TECH stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on TECH stock including scouring the social networks like TECH StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for TECH stock chart >>
Summary: Staar Surgical Company has evolved to become a developer, manufacturer and global distributor of products used by ophthalmologists and other eye care professionals to improve or correct vision in patients suffering from refractive conditions, cataracts and glaucoma.
- Recent STAA Stock Price: $102.03
- Yearly Gain for STAA stock: -36.72%
- Market Cap for STAA stock: $4.18B
- P/E Ratio for STAA stock: 148.505
Will STAA's stock price go up? Is there an accurate STAA stock forecast available?
TipRanks.com reports that Staar Surgical currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $110.40. The target pricing ranges from a high STAA forecast of $125.00 down to a low forecast of $97.00. Staar Surgical (STAA)’s last closing stock price was $102.03 which would put the average price target at 8.20% upside.
In addition, TradingView issued a Strong Buy rating for STAA stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on STAA stock.
Other analysts covering STAA include:
- David Saxon of Needham issued a Buy rating with the price target of $ 110 on 22 hours ago
- Bruce Jackson of Benchmark Co. issued a Buy rating with the price target of $ 117 on 22 hours ago
- Ryan Zimmerman of BTIG issued a Buy rating with the price target of $ 103 on 1 day ago
- Zachary Weiner of Jefferies issued a Buy rating with the price target of $ 125 on 1 day ago
If you are wondering if STAA is a good stock to buy, here are 3rd party ratings for STAA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Bottom 31% (175 out of 252)
What is the sentiment on the street regarding Staar Surgical? (Current ratings compiled by TipRanks.com)
- News Sentiment for STAA stock: Very Bullish
- Blogger Consensus for STAA stock: Bullish
- Media Buzz for STAA stock: Very High
- Insider Signal for STAA stock: Positive
- Investor Sentiment for STAA stock: Positive
- Hedge Fund signal for STAA stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on STAA stock including scouring the social networks like STAA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for STAA stock chart >>
Summary: NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
- Recent NEO Stock Price: $12.29
- Yearly Gain for NEO stock: -71.48%
- Market Cap for NEO stock: $1.48B
- P/E Ratio for NEO stock: -9.987
Will NEO's stock price go up? Is there an accurate NEO stock forecast available?
TipRanks.com reports that NeoGenomics currently has 7 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $16.00. The target pricing ranges from a high NEO forecast of $20.00 down to a low forecast of $9.00. NeoGenomics (NEO)’s last closing stock price was $12.29 which would put the average price target at 30.19% upside.
In addition, TradingView issued a n/a rating for NEO stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on NEO stock.
Other analysts covering NEO include:
- Tejas Savant of Morgan Stanley issued a Hold rating with the price target of $ 18 on 1 day ago
- Matthew Sykes of Goldman Sachs issued a Buy rating with the price target of $ 20 on 1 day ago
- Michael Matson of Needham issued a Buy rating with the price target of $ 16 on 2 days ago
- Puneet Souda of SVB Securities issued a Buy rating with the price target of $ 20 on 2 days ago
If you are wondering if NEO is a good stock to buy, here are 3rd party ratings for NEO stock:
- TipRanks.com: Moderate Buy
- TradingView.com: n/a
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 33% (82 out of 252)
What is the sentiment on the street regarding NeoGenomics? (Current ratings compiled by TipRanks.com)
- News Sentiment for NEO stock: Bullish
- Blogger Consensus for NEO stock: Bullish
- Media Buzz for NEO stock: High
- Insider Signal for NEO stock: Positive
- Investor Sentiment for NEO stock: Positive
- Hedge Fund signal for NEO stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on NEO stock including scouring the social networks like NEO StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for NEO stock chart >>
Summary: Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts.
- Recent ALDX Stock Price: $6.99
- Yearly Gain for ALDX stock: -18.27%
- Market Cap for ALDX stock: $451.25M
- P/E Ratio for ALDX stock: -6.81
Will ALDX's stock price go up? Is there an accurate ALDX stock forecast available?
TipRanks.com reports that Aldeyra Therapeutics currently has n/a analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is n/a. The target pricing ranges from a high ALDX forecast of n/a down to a low forecast of n/a. Aldeyra Therapeutics (ALDX)’s last closing stock price was $6.99 which would put the average price target at 206.58% upside.
In addition, TradingView issued a Buy rating for ALDX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ALDX stock.
Other analysts covering ALDX include:
- Marc Goodman of SVB Securities issued a Buy rating with the price target of $ 15 on 6 days ago
- Justin Kim of Oppenheimer issued a Buy rating with the price target of $ 13 on 4 weeks ago
- Yigal Nochomovitz of Citigroup issued a Buy rating with the price target of $ 26 on 2 months ago
- Matthew Cross of Alliance Global Partners issued a Buy rating with the price target of $ 24 on 2 months ago
If you are wondering if ALDX is a good stock to buy, here are 3rd party ratings for ALDX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 35% (87 out of 252)
What is the sentiment on the street regarding Aldeyra Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for ALDX stock: Very Bullish
- Blogger Consensus for ALDX stock: Bullish
- Media Buzz for ALDX stock: Medium
- Insider Signal for ALDX stock: Positive
- Investor Sentiment for ALDX stock: Very Positive
- Hedge Fund signal for ALDX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on ALDX stock including scouring the social networks like ALDX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ALDX stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================